Ocugen (OCGN) announced that the Data and Safety Monitoring Board, or DSMB, for the OCU410 ArMaDa clinical trial recently convened and approved continuation of the second phase of the Phase 1/2 study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback